Silverfin false false 30/06/2024 30/06/2024 01/07/2023 The principal activity of the Company during the financial year was that of an education provider. Orla Callan 03/07/2023 Luke Kiernan 03/07/2023 Muireann Macauliffe 28/03/2024 Neil McGowan 28/03/2024 Christopher Walsh 28/03/2024 12128137 2024-06-30 12128137 bus:Director1 2024-06-30 12128137 bus:Director2 2024-06-30 12128137 bus:Director3 2024-06-30 12128137 bus:Director4 2024-06-30 12128137 bus:Director5 2024-06-30 12128137 2023-06-30 12128137 core:CurrentFinancialInstruments 2024-06-30 12128137 core:CurrentFinancialInstruments 2023-06-30 12128137 2023-07-01 2024-06-30 12128137 bus:Micro-entities 2023-07-01 2024-06-30 12128137 bus:FilletedAccounts 2023-07-01 2024-06-30 12128137 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 12128137 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 12128137 bus:Director1 2023-07-01 2024-06-30 12128137 bus:Director2 2023-07-01 2024-06-30 12128137 bus:Director3 2023-07-01 2024-06-30 12128137 bus:Director4 2023-07-01 2024-06-30 12128137 bus:Director5 2023-07-01 2024-06-30 12128137 2022-07-01 2023-06-30 iso4217:GBP xbrli:pure

Company No: 12128137 (England and Wales)

INNOPHARMA EDU LIMITED

Unaudited Financial Statements
For the financial year ended 30 June 2024
Pages for filing with the registrar

INNOPHARMA EDU LIMITED

UNAUDITED FINANCIAL STATEMENTS

For the financial year ended 30 June 2024

Contents

INNOPHARMA EDU LIMITED

COMPANY INFORMATION

For the financial year ended 30 June 2024
INNOPHARMA EDU LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 30 June 2024
Directors Orla Callan (Appointed 03 July 2023)
Luke Kiernan (Appointed 03 July 2023)
Muireann Macauliffe (Appointed 28 March 2024)
Neil McGowan (Appointed 28 March 2024)
Christopher Walsh (Appointed 28 March 2024)
Secretary Orla Callan
Registered office 2nd Floor 168 Shoreditch High Street
London
E1 6RA
United Kingdom
Company number 12128137 (England and Wales)
Accountant Kreston Reeves LLP
37 St Margarets Street
Canterbury
Kent
CT1 2TU

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS
ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF INNOPHARMA EDU LIMITED

For the financial year ended 30 June 2024

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS
ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF INNOPHARMA EDU LIMITED (continued)

For the financial year ended 30 June 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Innopharma Edu Limited for the financial year ended 30 June 2024 which comprise the Balance Sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/regulation.

It is your duty to ensure that Innopharma Edu Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Innopharma Edu Limited. You consider that Innopharma Edu Limited is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the financial statements of Innopharma Edu Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

This report is made solely to the Board of Directors of Innopharma Edu Limited, as a body, in accordance with the terms of our engagement letter dated 12 June 2024. Our work has been undertaken solely to prepare for your approval the financial statements of Innopharma Edu Limited and state those matters that we have agreed to state to the Board of Directors of Innopharma Edu Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Innopharma Edu Limited and its Board of Directors as a body for our work or for this report.

Kreston Reeves LLP
Chartered Accountants

37 St Margarets Street
Canterbury
Kent
CT1 2TU

05 March 2025

INNOPHARMA EDU LIMITED

BALANCE SHEET

As at 30 June 2024
INNOPHARMA EDU LIMITED

BALANCE SHEET (continued)

For the financial year ended 30 June 2024
2024 2023
£ £
Current assets 234 234
Creditors: amounts falling due within one year ( 3,660) -
Net current (liabilities)/assets ( 3,426) 234
Total assets less current liabilities ( 3,426) 234
Accruals and deferred income ( 2,702) ( 2,200)
Net liabilities ( 6,128) ( 1,966)
Capital and reserves ( 6,128) ( 1,966)

For the financial year ending 30 June 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Innopharma Edu Limited (registered number: 12128137) were approved and authorised for issue by the Board of Directors on 05 March 2025 and were signed on its behalf by:

Orla Callan
Director
INNOPHARMA EDU LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 June 2024
INNOPHARMA EDU LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the For the financial year ended 30 June 2024

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 12128137). The address of its registered office is 2nd Floor 168 Shoreditch High Street, London, E1 6RA, United Kingdom.

The financial statements are presented in pounds sterling which is the functional currency of the company and rounded to the nearest £.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the financial year, including directors 5 2